REG - Venture Life Group - Notice of Results and Investor Presentation

Venture LifeAnnouncement

04/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240404:nRSD1994Ja&default-theme=true

RNS Number : 1994J  Venture Life Group PLC  04 April 2024

4 April 2024

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Notice of Results

and

Investor Presentation via Investor Meet Company

 

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market confirms that it will
release its results for the year ended 31 December 2023 on 9 April 2024.

The Company also announces that Jerry Randall (CEO) and Daniel Wells (CFO)
will provide a live presentation relating to the 2023 Full Year Results via
Investor Meet Company on 11 Apr 2024, 14:30 BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet
Venture Life Group plc via:

https://www.investormeetcompany.com/venture-life-group-plc/register-investor
(https://www.investormeetcompany.com/venture-life-group-plc/register-investor)

Investors who already follow Venture Life Group plc on the Investor Meet
Company platform will automatically be invited.

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7720 0500
 Stephen Keys/Camilla Hume (Corporate Finance)

 Michael Johnson (Sales)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The
Netherlands and Sweden, the Group's product portfolio includes some key
products such as the Balance Active range in the area of women's intimate
healthcare, the Earol® product line in ENT care, the Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, the
UltraDEX and Dentyl oral care product ranges, products for fungal infections
and proctology, and dermo-cosmetics for addressing the signs of ageing. Its
products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations
in Italy and Sweden, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUOOORSVUSRAR